Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

• US 20030219752A1
• Filed: 05/17/2002
• Published: 11/27/2003
• Est. Priority Date: 12/07/1995
• Status: Abandoned Application

• Current Assignee: Diversa Corporation (BASF SE)
• Original Assignee: Diversa Corporation (BASF SE)
• Inventors: Short, Jay M.
• Application Number:
  US10/151,469
• Publication Number:
  US 20030219752A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 16/005 constructed by phage libraries
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The invention is directed to methods for generating sets, or libraries, of nucleic acids encoding antigen-binding sites, such as antibodies, antibody domains or other fragments, including single and double stranded antibodies, major histocompatibility complex (MHC) molecules, T cell receptors (TCRs), and the like. This invention provides methods for generating variant antigen binding sites, e.g., antibodies and specific domains or fragments of antibodies (e.g., Fab or Fc domains), by altering template nucleic acids including by saturation mutagenesis, synthetic ligation reassembly, or a combination thereof. In one aspect, invention provides methods for generating all human or humanized antibodies and evolving them to achieve optimized properties related to stability, duration, expression, production, enzymatic activity, affinity, avidity, localization, and other immunological properties. Polypeptides generated by these methods can be analyzed using a novel capillary array platform, which provides unprecedented ultra-high throughput screening.

Claims

1. A method for producing a library of nucleic acids encoding a plurality of modified antigen binding sites, wherein the modified antigen binding sites are derived from a first nucleic acid comprising a sequence encoding a first antigen binding site, the method comprising:

(a) providing a first nucleic acid encoding a first antigen binding site;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

(c) using the set of mutagenic oligonucleotides to generate a set of antigen binding site-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of modified antigen binding sites.

2. The method of claim 1, wherein step (b) provides a set of mutagenic oligonucleotides that encode all nineteen naturally-occurring amino acid variants for each targeted codon, thereby generating all 19 possible natural amino acid changes at each amino acid codon mutagenized.

3. The method of claim 1, further comprising expressing the set of variant antigen binding site-encoding nucleic acids such that antigen binding site-encoding polypeptides encoded by the variant nucleic acids are expressed.

4. The method of claim 1, wherein the set of mutagenic oligonucleotides comprises a 19-fold degenerate mutagenic oligonucleotide for each codon to be mutagenized, wherein each of the 19-fold degenerate mutagenic oligonucleotides comprises a homologous first sequence and a degenerate triplet second sequence.

5. The method of claim 1, wherein the antigen binding site comprises a single stranded antigen binding polypeptide, a Fab fragment, an Fc fragment, a Fd fragment, a F(ab′

)₂ fragment, a Fv fragment or a complementarity determining region (CDR).

6. The method of claim 5, wherein the antigen binding site polypeptide further comprises an antibody polypeptide.

7. The method of claim 1, wherein the antigen binding site polypeptide further comprises an antigen binding site of a T cell receptor (TCR).

8. The method of claim 7, wherein the antigen binding site polypeptide further comprises a T cell receptor (TCR).

9. The method of claim 1, wherein the antigen binding site polypeptide further comprises an antigen binding site of a major histocompatibility complex (MHC) molecule.

10. The method of claim 9, wherein the antigen binding site polypeptide further comprises a major histocompatibility complex (MIC) molecule.

11. The method of claim 10, wherein the major histocompatibility complex (MRC) molecule comprises a Class I molecule.

12. The method of claim 10, wherein the major histocompatibility complex (MHC) molecule comprises a Class II molecule.

13. The method of claim 1, wherein the nucleic acid of step (a) is derived from a nucleic acid encoding a mammalian polypeptide.

14. The method of claim 13, wherein the mammalian polypeptide comprises a human polypeptide.

15. The method of claim 13, wherein the mammalian polypeptide is selected from the group consisting of an antibody, a T cell receptor, a Class I MHC molecule and a Class II MHC molecule.

16. The method of claim 1, wherein the nucleic acid of step (a) is derived from a human nucleic acid encoding an antigen binding site.

17. The method of claim 16, wherein the nucleic acid of step (a) is derived from a phage comprising a human nucleic acid sequence encoding an antigen binding site, wherein the phage expresses the antigen binding site.

18. The method of claim 16, wherein the nucleic acid of step (a) is derived from a non-human mammal comprising a human nucleic acid sequence encoding an antigen binding site, wherein the non-human mammal expresses the antigen binding site.

19. The method of claim 18, wherein the non-human mammal is a transgenic non-human mammal.

20. The method of claim 19, wherein the transgenic non-human mammal is a mouse.

21. The method of claim 1, wherein at least two amino acid codons in the antigen binding site are mutagenized.

22. The method of claim 21, wherein all the amino acid codons in the antigen binding site are mutagenized.

23. The method of claim 6, wherein all the amino acid codons in the antibody polypeptide are mutagenized.

24. The method of claim 8, wherein all the amino acid codons in the T cell receptor (TCR) are mutagenized.

25. The method of claim 10, wherein all the amino acid codons in the MHC molecule are mutagenized.

26. The method of claim 1, wherein a degenerate mutagenic oligonucleotide comprises a first homologous sequence, a degenerate triplet second sequence, and a third homologous sequence.

27. The method of claim 1, wherein each degenerate oligonucleotide comprises a first homologous sequence, a plurality of degenerate triplets second sequences, and a third homologous sequence.

28. The method of claim 3, further comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen.

29. The method of claim 28, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen capable of being specifically bound by the first antigen binding site polypeptide.

30. The method of claim 29, comprising identifying an antigen binding site variant by its increased antigen binding affinity or antigen binding specificity as compared to the affinity or specificity of the first antigen binding site to the antigen.

31. The method of claim 29, comprising identifying an antigen binding site variant by its decreased antigen binding affinity or antigen binding specificity as compared to the affinity or specificity of the first antigen binding site to the antigen.

32. The method of claim 1, further comprising mutagenizing the first nucleic acid of step (a) by a method comprising an optimized directed evolution system.

33. The method of claim 1, further comprising mutagenizing the first nucleic acid of step (a) by a method comprising a synthetic ligation reassembly.

34. The method of claim 3, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising expression of the expressed antigen binding site polypeptide in a solid phase.

35. The method of claim 34, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising a capillary array.

36. The method of claim 34, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising a double-orificed container.

37. The method of claim 36, wherein the double-orificed container comprises a double-orificed capillary array.

38. The method of claim 37, wherein the double-orificed capillary array is a GIGAMATRIX™

capillary array.

39. The method of claim 34, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising use of an ELISA.

40. The method of claim 3, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising phage display of the antigen binding site polypeptide.

41. The method of claim 3, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising expression of the expressed antigen binding site polypeptide in a liquid phase.

42. The method of claim 3, comprising screening the expressed antigen binding site polypeptide for its ability to specifically bind an antigen by a method comprising ribosome display of the antigen binding site polypeptide.

43. The method of claim 1, wherein the set of progeny antigen binding site-encoding variant nucleic acids is generated by amplifying the nucleic acid of step (a) by a polymerase-based amplification using a plurality of oligonucleotides.

44. The method of claim 43, wherein the amplification comprises a polymerase chain reaction (PCR).

45. A library of nucleic acids encoding a plurality of modified antigen binding sites, wherein the modified antigen binding sites are derived from a first nucleic acid comprising a sequence encoding a first antigen binding site, made by a method comprising the following steps:

(a) providing a first nucleic acid encoding a first antigen binding site;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

(c) using the set of mutagenic oligonucleotides to generate a set of antigen binding site-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of modified antigen binding sites.

46. A method for producing from a library of variant antibodies from a template antibody, the method comprising:

(a) providing a first nucleic acid encoding the template antibody;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of antibody-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant antibodies.

47. The method of claim 46, wherein step (b) provides a set of mutagenic oligonucleotides that encode all nineteen naturally-occurring amino acid variants for each targeted codon, thereby generating all 19 possible natural amino acid changes at each amino acid codon mutagenized.

48. The method of claim 46, wherein the antibody is selected from the group consisting of polypeptides comprising a Fab fragment, an Fd fragment, an Fc fragment, a F(ab′

)2 fragment, a Fv fragment and a complementarity determining region (CDR).

49. The method of claim 46, wherein the plurality of oligonucleotides comprises a degenerate oligonucleotide for each codon to be mutagenized, wherein each of the degenerate oligonucleotides comprises a homologous first sequence and a degenerate triplet second sequence.

50. The method of claim 46, wherein the set of progeny polynucleotides encoding antibodies is generated by amplifying the nucleic acid of step (a) using a plurality of oligonucleotides.

51. A library of variant antibodies derived from a template antibody made by a method comprising the following steps:

(a) providing a first nucleic acid encoding the template antibody;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of antibody-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant antibodies.

52. A method for producing from a library of variant T cell receptors (TCRs) from a template T cell receptor (TCR), the method comprising:

(a) providing a first nucleic acid encoding the template T cell receptor;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of T cell receptor (TCR)-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant T cell receptors (TCRs).

53. A library of variant T cell receptors (TCRs) derived from a template T cell receptor (TCR) made by a method comprising the following steps:

(a) providing a first nucleic acid encoding the template T cell receptor;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of T cell receptor (TCR)-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant T cell receptors (TCRs).

54. A method for producing from a library of variant major histocompatibility complex (MHC) molecules from a template major histocompatibility complex (MHC) molecule, the method comprising:

(a) providing a first nucleic acid encoding the template major histocompatibility complex (MHC) molecule;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of major histocompatibility complex (MHC) molecule-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant major histocompatibility complex (MHC) molecules.

55. A library of variant major histocompatibility complex (MHC) molecules derived from a template major histocompatibility complex (MHC) molecule made by a method comprising the following steps:

(a) providing a first nucleic acid encoding the template major histocompatibility complex (MIC) molecule;

(b) providing a set of mutagenic oligonucleotides that encode naturally-occurring amino acid variants at a plurality of targeted codons in the first nucleic acid; and

,

c) using the set of mutagenic oligonucleotides to generate a set of major histocompatibility complex (MHC) molecule-encoding variant nucleic acids encoding a range of amino acid variations at each amino acid codon that was mutagenized,

thereby producing a library of nucleic acids encoding a plurality of variant major histocompatibility complex (MHC) molecules.

56. A method of making a set of nucleic acids encoding a set of antigen binding site variants comprising the steps of:

(a) providing a template nucleic acid encoding an antigen-binding polypeptide;

(b) providing a plurality of oligonucleotides that encode all nineteen naturally-occurring amino acid variants at a single amino acid residue of the antigen-binding polypeptide; and

,

(c) generating a set of progeny antigen binding site-encoding variant nucleic acids encoding a non-stochastic range of single amino acid substitutions at each amino acid codon that was mutagenized, whereby all 19 possible natural amino acid changes are generated at each amino acid codon mutagenized,

thereby making a set of nucleic acids encoding a set of antigen binding site variants.

57. The method of claim 56, further comprising expressing the set of progeny antigen binding site-encoding polynucleotides such that antigen binding site-encoding polypeptides encoded by the progeny polynucleotides are expressed.

58. The method of claim 56, wherein the plurality of oligonucleotides comprises a set of degenerate oligonucleotides and each of the degenerate oligonucleotides comprises a homologous first sequence and a degenerate triplet second sequence.

59. The method of claim 56, wherein the antigen binding site-encoding polypeptide comprises a single stranded antigen binding polypeptide.

60. The method of claim 56, wherein the antigen binding site-encoding polypeptide comprises an antibody polypeptide.

61. The method of claim 56, wherein the antigen binding site-encoding polypeptide comprises an antigen binding site of a T cell receptor (TCR).

62. The method of claim 61, wherein the antigen binding site-encoding polypeptide further comprises a T cell receptor (TCR).

63. The method of claim 56, wherein the antigen binding site-encoding polypeptide comprises an antigen binding site of a major histocompatibility complex (MHC) molecule.

64. The method of claim 63, wherein the antigen binding site-encoding polypeptide further comprises a major histocompatibility complex (MHC) molecule.

65. The method of claim 56, wherein the nucleic acid of step (a) is derived from a nucleic acid encoding a mammalian antibody polypeptide.

66. The method of claim 65, wherein the nucleic acid of step (a) is derived from a human nucleic acid.

67. The method of claim 56, wherein at least two amino acid codons in the antigen binding site are mutagenized and a set of degenerate oligonucleotides that encode all nineteen naturally-occurring amino acid variants are provided for each amino acid codon mutagenized.

68. The method of claim 56, wherein all the amino acid codons in the antigen binding site are mutagenized and a set of degenerate oligonucleotides that encode all nineteen naturally-occurring amino acid variants are provided for each amino acid codon mutagenized.

69. The method of claim 60, wherein all the amino acid codons in the antibody polypeptide are mutagenized.

70. The method of claim 61, wherein all the amino acid codons in the antigen binding site of the T cell receptor (TCR) are mutagenized.

71. The method of claim 63, wherein all the amino acid codons in the antigen binding site of the major histocompatibility complex (MHC) molecule are mutagenized.

72. The method of claim 56, wherein a degenerate oligonucleotide comprises a first homologous sequence, a degenerate triplet second sequence, and a homologous third sequence.

73. The method of claim 56, wherein each degenerate oligonucleotide comprises a first homologous sequence, a degenerate triplet second sequence, and a homologous third sequence.

74. The method of claim 57, further comprising screening an expressed antigen binding site-encoding polypeptide for its ability to specifically bind an antigen.

75. The method of claim 57, comprising screening the expressed antigen binding site-encoding polypeptide for its ability to specifically bind an antigen capable of being specifically bound by the first antigen binding site.

76. The method of claim 75, comprising identifying an antigen binding site variant by its increased antigen binding affinity or antigen binding specificity to the antigen as compared to the affinity or specificity of the antigen binding site encoded by the nucleic acid of step (a).

77. The method of claim 56, further comprising mutagenizing the template nucleic acid by a method comprising an optimized directed evolution system.

78. The method of claim 56, further comprising mutagenizing the template nucleic acid by a method comprising a synthetic ligation reassembly.

79. The method of claim 56, comprising screening the expressed antigen binding site-encoding polypeptide for its ability to specifically bind an antigen by a method comprising a capillary array.

80. The method of claim 56, comprising screening the expressed antigen binding site-encoding polypeptide for its ability to specifically bind an antigen by an ELISA.

81. The method of claim 56, wherein the set of variant nucleic acids is generated by performing amplification reactions on the nucleic acid of step (a) using the set of oligonucleotides to generate a set of variant nucleic acids encoding nineteen amino acid substitution variants at a single amino acid residue of the antigen-binding polypeptide.

82. The method of claim 81, wherein the amplification comprises a polymerase-based amplification.

83. The method of claim 82, wherein polymerase-based amplification comprises a polymerase chain reaction (PCR).

84. The method of claim 56, wherein the set of variant nucleic acids comprises 10¹⁰ members.

85. The method of claim 56, wherein the set of variant nucleic acids comprises 10⁵ members.

86. The method of claim 56, wherein the set of variant nucleic acids comprises 10³ members.

87. A method of making a set of antibody variants comprising the steps of:

(a) providing a nucleic acid encoding an antibody;

(b) providing a plurality of oligonucleotides;

(c) generating a non-stochastic range of single amino acid substitutions at each amino acid codon, whereby all 19 possible natural amino acid changes are generated at each amino acid codon mutagenized, thereby generating a set of variant nucleic acids; and

,

(d) expressing the set of variant nucleic acids such that the antibody variants encoded by the variant nucleic acids are expressed.

88. The method of claim 87, wherein the antibody is selected from the group consisting of polypeptides comprising a Fab fragment, a Fd fragment, an Fc fragment, a F(ab′

)2 fragment, a Fv fragment and a complementarity determining region (CDR).

89. The method of claim 87, wherein the plurality of oligonucleotides comprises a set of degenerate oligonucleotides that encode all nineteen naturally-occurring amino acid variants at a single amino acid residue of the antibody, wherein each of the degenerate oligonucleotides comprises a homologous first sequence and a degenerate triplet second sequence.

90. The method of claim 87, wherein generating a non-stochastic range of single amino acid substitutions comprises performing amplification reactions on the nucleic acid of step (a) using the set of oligonucleotides to generate a set of variant nucleic acids encoding nineteen amino acid substitution variants at a single amino acid residue of the antibody.

91. A method of identifying a variant of an antigen binding site comprising the steps of:

(a) providing a nucleic acid encoding an antigen binding site;

(b) providing a set of oligonucleotides that encode all nineteen naturally-occurring amino acid variants at all residues of the antigen-binding site;

(c) incorporating the sequence of the oligonucleotides of step (b) into the nucleic acid of step (a) to generate a set of variant nucleic acids encoding nineteen amino acid substitution variants at each residue of the antigen binding site;

(d) expressing each of the variant nucleic acids as polypeptides and measuring the variant'"'"'s affinity to the antigen; and

,

(e) identifying a variant of the antigen binding site by its increased or decreased antigen binding specificity as compared to the antigen binding affinity of the antigen binding site encoded by the nucleic acid of step (a).

92. The method of claim 91, wherein the variant nucleic acids are expressed using in vitro transcription/translation.

93. The method of claim 91, wherein the variant nucleic acids are expressed using phage display.

94. The method of claim 91, wherein the variant nucleic acids are expressed using f2o ribosome display.

95. The method of claim 91, wherein the variant nucleic acids are expressed using a double orificed container.

96. The method of claim 95, wherein the variant nucleic acids are expressed using a double orificed capillary array.

97. The method of claim 91, wherein the set of oligonucleotides comprises a set of degenerate oligonucleotides that encode all nineteen naturally-occurring amino acid variants at a single amino acid residue of the antibody, wherein each of the degenerate oligonucleotides comprises a homologous first sequence and a degenerate triplet second sequence.

98. The method of claim 91, wherein the antigen binding site comprises an antibody.

99. The method of claim 98, wherein the antibody is selected from the group consisting of polypeptides comprising a Fab fragment, an Fd fragment, an Fc fragment, a F(ab′

)2 fragment, a Fv fragment and a complementarity determining region (CDR).

100. The method of claim 91, wherein the antigen binding site comprises an antigen binding site of a T cell receptor.

101. The method of claim 91, wherein the antigen binding site comprises an antigen binding site of a major histocompatibility complex molecule.

102. The method of claim 91, wherein incorporating the sequence of the oligonucleotides of step (b) into the nucleic acid of step (a) is accomplished by an amplification reaction using the oligonucleotides as primers.